413 5. Complicanze precoci [29] Neelis E. et al. Growth, Body Composition, and Micronutrient Abnormalities During and After Weaning Off Home Parenteral Nutrition. Journal of Pediatric Gastroenterology and Nutrition: November 2018 - Volume 67 - Issue 5 - p e95-e100. doi: 10.1097/ MPG.0000000000002090 [30] Ukleja A. Weaning from Parenteral Nutrition. Gastroenterol Clin N Am 48 (2019) 525–550. doi: https://doi.org/10.1016/j. gtc.2019.08.007 [31] Harshitha K., Chamberlain R. S. Immunonutrition Is Associated with a Decreased Incidence of Graft-Versus-Host Disease in Bone Marrow Transplant Recipients: A Meta-Analysis JPEN J Parenter Enteral Nutr. 2017 Nov;41(8):1286-1292. doi: 10.1177/0148607116663278. [32] Clemmons AB, Orr J, Andrick B, Gandhi A, Sportes C, DeRemer D. Randomized, placebo-controlled, phase III trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) versus FOND Plus Olanzapine (FOND-O) for the prevention of chemotherapyinduced nausea and vomiting in patients with hematologic malignancies receiving highly emetogenic chemotherapy and hematopoietic cell transplantation regimens: the FOND-O trial. Biol Blood Marrow Transpl. 2018; 24:2065–71. https://doi.org/10.1016/j. bbmt.2018.06.005. [33] August DA, Huhmann MB, American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors. A.S.P.E.N. clinical guidelines: nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation. J Parenter Enter Nutr. 2009; 33:472–500. https://doi. org/10.1177/0148607109341804. [34] Fuji S. et al. How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT. Bone Marrow Transplantation volume 51, pages1041–1049 (2016). doi: https://doi. org/10.1038/bmt.2016.81 [35] Schumachera M. V., Faulhaberb G. A. M. Nutritional status and hyperglycemia in the peritransplant period: a review of associations with parenteral nutrition and clinical outcomes. Revista Brasileira de Hematologia e Hemoterapia Volume 39, Issue 2, April–June 2017, Pages 155-162 doi: https://doi.org/10.1016/j. bjhh.2016.09.016 [36] Seguy D et al. Better Outcome of Patients Undergoing Enteral Tube Feeding After Myeloablative Conditioning for Allogeneic Stem Cell Transplantation. Transplantation, Volume 94, Number 3, August 15, 2012. doi: 10.1097/TP.0b013e3182558f60 [37] Staffas A., Burgos da Silva M., van den Brink M. R. M. The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease. Blood, 23 february 2017 x volume 129, number 8. doi: https://doi.org/10.1182/blood-2016-09-691394 [38] Shono Y., van den Brink M. R. M. Gut microbiota injury in allogeneic haematopoietic stem cell transplantation. Nature Reviews Cancer volume 18, pages283–295 (2018). doi: https://doi. org/10.1038/nrc.2018.10 [39] Gonzales F. et al. Better early outcome with enteral rather than parenteral nutrition in children undergoing MAC allo-SCT. Clin. Nutr. 2018;3 7:2113–21. doi: https://doi.org/10.1016/j. clnu.2017.10.005 [40] Williams-Hooker R., Adams M., Havrilla D. A., Leung W., Roach R.R., Mosby T. Caregiver and Health Care Provider Preferences of Nutritional Support in a Hematopoietic Stem Cell Transplant Unit. Pediatr Blood Cancer 2015; 62:1473–1476. Doi: 10.1002/ pbc.25473
RkJQdWJsaXNoZXIy ODUzNzk5